StreetInsider.com News Articles

Form 8-K Korro Bio, Inc. For: Oct 22

Thu, 22 Oct 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20261022/27218844.html

Korro Bio reports preclinical data for AATD drug candidate KRRO-111

Thu, 22 Oct 2026 07:00:24 -0400

Korro Bio, Inc. (Nasdaq: KRRO) announced preclinical results for KRRO-111, its RNA-editing drug candidate for alpha-1 antitrypsin deficiency (AATD), according to a company press release.

In repeat-dose mouse studies, KRRO-111 achieved up to 96% SERPINA1 mRNA editing, with M-AAT comprising 93% of total circulating AAT. Total AAT concentrations reached 172 μM, approximately six times higher than vehicle control at Day 57. The compound also reduced whole liver Z-AAT levels by 95% relative to vehicle control in immunocompetent mice.

KRRO-111 is a GalNAc-conjugated RNA-editing oligonucleotide administered subcutaneously. It targets liver cells and uses endogenous ADAR enzymes to correct the pathogenic SERPINA1 transcript, enabling

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Thu, 22 Oct 2026 07:00:00 -0400

Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold

KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver

Best-in-class preclinical profile supports KRRO-111’s potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027

CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its novel oligonucleotide promoted editing of RNA (OPERA^®)

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

Thu, 22 Oct 2026 07:00:00 -0400

Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold

KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver

Best-in-class preclinical profile supports KRRO-111’s potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 16:05:00 -0400

CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 4,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $8.88 per share, the closing price per share of Korro's common stock as reported by Nasdaq

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 16 Oct 2026 16:05:00 -0400

H.C. Wainwright Reiterates Buy Rating on Korro Bio Inc. (KRRO)

Tue, 06 Oct 2026 07:04:54 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $15.00 price target on Korro Bio Inc. (NASDAQ: KRRO).

The analyst commented: "Yesterday, Korro Bio reported that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the company’s GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and patients with hepatic encephalopathy (HE). This trial is currently enrolling healthy volunteers in Australia and is part of a global Phase 1/2 trial program entitled ANCHOR (AssessmeNt of Control of Hyperammonemia through Oligonucleotide-based RNA editing).

Form 8-K Korro Bio, Inc. For: Oct 05

Mon, 05 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261005/27148867.html

Korro Bio doses first cohort in Phase 1/2 trial for KRRO-121

Mon, 05 Oct 2026 16:05:12 -0400

Korro Bio, Inc. (Nasdaq: KRRO) announced that the first cohort of healthy volunteers has been dosed in its Phase 1/2 clinical trial, known as ANCHOR, for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide being developed for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE).

The initial cohort received a single dose of 2mg/kg. The trial is currently enrolling healthy volunteers in Australia. According to a company statement, the ANCHOR program consists of two parts: a Phase 1 single ascending dose (SAD) study followed by a multiple ascending dose (MAD) study in up to 50 healthy volunteers, and a Phase

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

Mon, 05 Oct 2026 16:05:00 -0400

Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background
Administered a single dose of 2mg/kg to the first cohort of healthy volunteers
Expected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027

CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

Mon, 05 Oct 2026 16:05:00 -0400

Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background
Administered a single dose of 2mg/kg to the first cohort of healthy volunteers
Expected to start dosing in UCD patients in the first half of 2027 with an interim readout expected in the second half of 2027

Form 4 Korro Bio, Inc. For: Sep 11 Filed by: FORMELA JEAN FRANCOIS

Tue, 15 Sep 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260915/27065046.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Mon, 14 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260914/27059126.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Mon, 14 Sep 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260914/27059124.html

Form 4 Korro Bio, Inc. For: Sep 11 Filed by: Dolan Oliver

Mon, 14 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27058402.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Fund XI, L.P.

Fri, 11 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27053640.html

Form 144 Korro Bio, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Fri, 11 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260911/27053633.html

Form 144 Korro Bio, Inc. Filed by: Dolan Oliver

Fri, 11 Sep 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260911/27053167.html

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 11 Sep 2026 16:05:00 -0400

CAMBRIDGE, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to three newly hired employees.

Korro granted the new employees nonstatutory stock options to purchase 5,000 shares of Korro’s common stock, in the aggregate, at an exercise price of $12.93 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Fri, 11 Sep 2026 16:05:00 -0400

Form 4 Korro Bio, Inc. For: Sep 08 Filed by: Dolan Oliver

Thu, 10 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260910/27048373.html

Form 4 Korro Bio, Inc. For: Aug 26 Filed by: FORMELA JEAN FRANCOIS

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998488.html

Form 4 Korro Bio, Inc. For: Aug 26 Filed by: FORMELA JEAN FRANCOIS

Fri, 28 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260828/26998488.html

Korro to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:

Citi 2026 Biopharma Back to School Summit
Format: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, Citi
Date: September 9^th, 2026
Time: 8:40 AM ET

2026 Cantor Global Healthcare Conference
Format: Fireside

Korro to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

Citi 2026 Biopharma Back to School Summit
Format: Fireside chat moderated by Yigal Nochomovitz, Ph.D., Director, Biotech Equity Research, Citi
Date: September 9^th, 2026
Time: 8:40 AM ET

2026 Cantor Global Healthcare Conference
Format: Fireside